What question did this study set out to answer?

To evaluate the effectiveness of clindamycin in treating bacteremic M1UK Streptococcus pyogenes pneumonia.

April 30, 2026International Journal of Infectious Diseases1 citationsOpen Access

Clindamycin demonstrates clinical effectiveness for bacteremic M1UK Streptococcus pyogenes pneumonia: A case report and in vitro evidence of notable antitoxin effects on M1UK

MEMasayoshi Ezaki TNTien Manh Nguyen HKHitoshi Kawasuji

Key Points

To evaluate the effectiveness of clindamycin in treating bacteremic M1UK Streptococcus pyogenes pneumonia.
Reported a case of an immunocompetent patient with bacteremic pneumonia treated with clindamycin.
Conducted in vitro tests to assess clindamycin's effect on streptococcal pyrogenic exotoxin A expression in M1UK and M1global strains.
Clindamycin improved the clinical condition of the patient.
In vitro tests showed clindamycin suppressed speA expression in M1UK strains but not in M1global strains.
Levofloxacin did not demonstrate a suppressive effect on exotoxin expression.

Abstract

We report a case of bacteremic M1UK Streptococcus pyogenes pneumonia in an immunocompetent patient, which improved with adjunctive clindamycin therapy.In vitro, clindamycin consistently suppressed expression of streptococcal pyrogenic exotoxin A (speA) in M1UK strains but not in the M1global strain, whereas levofloxacin showed no suppressive effect.These findings support a potential antitoxin role of clindamycin in M1UK infections.

AIに質問

Bookmark

View Full Paper